Literature DB >> 23702563

Stability of sample solution as a crucial point during HPLC determination of chemical purity of temozolomide drug substance.

Łukasz Jedynak1, Maria Puchalska, Marta Zezula, Marta Łaszcz, Wojciech Łuniewski, Joanna Zagrodzka.   

Abstract

An HPLC method for determination of related substances in temozolomide drug substance was developed. Particular attention was paid to the stability studies due to the fact that temozolomide is unstable in a solution and quickly decomposes to its main degradation product 5-amino-4-imidazolecarboxamide (AIC). A mixture of diluted acetic acid and acetonitrile (4:1, v/v) as a diluent guaranteed lowering the decomposition of temozolomide in the solution. As it is not practically possible to fully eliminate the decomposition of temozolomide during an analysis, the mathematical correction of the results was proposed which allows to analyse almost five times more samples per week, comparing to the procedure without the application of the correction. The accuracy of the correction procedure was proved by investigating the recovery of AIC spiked to temozolomide solutions at different levels. Recoveries equalled 90-108% for AIC concentrations contained in the range of 0.30-1.80 μg ml(-1). The developed method was validated according to the current guidelines, proving the suitability of the method for its intended purpose.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23702563     DOI: 10.1016/j.jpba.2013.04.032

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  4 in total

1.  Thermoresponsive nanocomposite gel for local drug delivery to suppress the growth of glioma by inducing autophagy.

Authors:  Li Ding; Qi Wang; Ming Shen; Ying Sun; Xiangyu Zhang; Can Huang; Jianhua Chen; Rongxin Li; Yourong Duan
Journal:  Autophagy       Date:  2017-06-08       Impact factor: 16.016

2.  Development of a Hospital Compounded, Taste-Masked, Temozolomide Oral Suspension and 5-Year Real-Life Experience in Treating Paediatric Patients.

Authors:  Maxime Annereau; Mélanie Hinterlang; Hugues Bienayme; Gilles Vassal; Antoine Pinon; Mathieu Schmitt; Lucas Denis; Caroline Lemarchand; Laurent Martin; François Lemare; Samuel Abbou; Jérémy Bastid; Lionel Tortolano
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-29

3.  Development and Full Validation of a Stability-indicating HPLC Method for the Determination of the Anticancer Drug Temozolomide in Pharmaceutical Form.

Authors:  Evin Kapçak; Eda Hayriye Şatana-Kara
Journal:  Turk J Pharm Sci       Date:  2018-11-20

4.  Identification and physicochemical characteristics of temozolomide process-related impurities.

Authors:  Marta Łaszcz; Marek Kubiszewski; Lukasz Jedynak; Monika Kaczmarska; Łukasz Kaczmarek; Wojciech Łuniewski; Krzysztof Gabarski; Anna Witkowska; Krzysztof Kuziak; Maura Malińska
Journal:  Molecules       Date:  2013-12-11       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.